Solid tumor cancer cells

Solid tumor cancer cells are the malignant cellular components of abnormal tissue masses that lack liquid or cystic areas, distinguishing them from hematologic malignancies like leukemias (NCI Dictionary, 2024). These cells are characterized by the hallmarks of cancer, such as sustained proliferative signaling, evasion of growth suppressors, and the induction of angiogenesis to support nutrient delivery (Hanahan & Weinberg, Cell, 2011). In the context of drug discovery, 'solid tumor cancer cells' is a broad category rather than a specific molecular target, encompassing a wide variety of histological types including carcinomas and sarcomas. These cells interact with a diverse array of therapeutic agents, ranging from traditional cytotoxic chemotherapies that damage DNA to modern targeted therapies and immunotherapies that exploit specific genetic mutations or surface proteins (NIH, 2023). A significant challenge in treating solid tumors is the complex tumor microenvironment and the inherent genetic instability of the cells, which frequently leads to the development of multi-drug resistance (Nature Reviews Cancer, 2020). Consequently, clinical management often requires a multi-modal approach tailored to the specific molecular profile of the tumor.

Other names

Solid tumorsMalignant solid neoplasmsSolid cancerSolid malignancy

Drugs targeting solid tumor cancer cells act through various mechanisms including DNA alkylation, microtubule inhibition, immune checkpoint blockade, and inhibition of signal transduction pathways (NIH, 2023; Nature Reviews Cancer, 2020).